Form 4: Iovance Biotherapeutics COO Igor Bilinsky Reports Stock Transactions
SEC Form 4 Filing
Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On September 3, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, had restricted stock units (RSUs) vest, resulting in the acquisition of 3,516 and 23,438 shares of common stock.
- The vesting of these RSUs was a non-cash transaction.
- To cover mandatory tax withholding requirements, Iovance Biotherapeutics withheld 1,784 and 11,891 shares at a price of $10.85 per share.
- Following these transactions, Bilinsky directly owns 54,422 shares of Iovance Biotherapeutics common stock and 23,437 restricted stock units.
- The remaining RSUs will vest in equal quarterly installments or on the one-year anniversary of the initial grant date.
Sentiment
Score: 5
Explanation: This is a neutral event related to executive compensation and does not inherently indicate positive or negative sentiment.
Future Outlook
The remaining RSUs will vest in equal quarterly installments or on the one-year anniversary of the initial grant date.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| March 2, 2023 | Date of grant for some of the restricted stock units. |
| March 1, 2024 | Date of grant for some of the restricted stock units. |
| 09/03/2024 | Date of RSU vesting and share withholding. |
| 09/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.